OmniComm forms agreement with Miami Heart Research Institute



Under the terms of the agreement, OmniComm's data collection and management solution TrialMaster, will be used by 10 clinical sites, plus a data coordinating center, a clinical coordinating center, an endothelial function and oxidative stress core lab and a central pharmacy. The clinical trial, PACT, is a trial of chelation therapy, an alternative medicine modality, which requires instantaneous communication between clinical sites and a central pharmacy to adjust infusion doses. Through the agreement, OmniComm will collect clinical data, shipment and receipt data and laboratory data.

"With this study we begin the critical pioneering effort to break down the barriers between 'traditional' and 'alternative' medicine, to explore all avenues to further medical knowledge and improve patient care," said Paul Kurlansky, Director of Research and Co-Principal Investigator. "The state-of-the-art data collection systems provided by OmniComm enable us to integrate the complex elements of this study in the most effective manner possible."

"This trial again gives OmniComm the ability to implement our real-time communication and data collection technology," said David Ginsberg, CEO of OmniComm. "In this case, our Web-based application will be used to link together the important pieces of a clinical trial, sites, pharmacy and labs, to improve workflow, accuracy and speed."